To Cycle or Fight - CDK 4/6 Inhibitors at the Crossroads of Anti-Cancer Immunity

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1999
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

First CDK 4/6 Inhibitor Heads to Market

Cancer Discovery
Oncology
2015English

Recent Advances in CDK Inhibitors for Cancer Therapy

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2018English

Complementing the Cancer-Immunity Cycle

Frontiers in Immunology
AllergyImmunology
2019English

Science at the Crossroads: Fact or Fiction?

Journal of Medical Biochemistry
BiochemistryClinical Biochemistry
2011English

Theology at the Crossroads: Philosophical or Historical Theology?

Vestnik Pravoslavnogo Sviato-Tikhonovskogo Gumanitarnogo Universiteta, Seria I. Bogoslovie, Filosofia, Religiovedenie
PhilosophyReligious StudiesHistory
2015English

Antiangiogenic Agents and HIF-1 Inhibitors Meet at the Crossroads

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2009English

Th17 Cells at the Crossroads of Innate and Adaptive Immunity Against Infectious Diseases at the Mucosa

Mucosal Immunology
AllergyImmunology
2009English

Releasing the Brakes to Fight Cancer

EMBO Reports
BiochemistryGeneticsMolecular Biology
2016English

Resistance to Apoptosis Conferred by CDK Inhibitors During Myocyte Differentiation

Science
MultidisciplinaryPhilosophy of ScienceHistory
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy